Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
The incidence of uterine cancer in Russia increased by 28.8 % over the last 10 years. This trend is partly associated with an increasing prevalence of overweight and aging of the female population. Despite the fact that uterine cancer is limited to the uterine body in 84 % of cases, searching for ne...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-05-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/940 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849773630921113600 |
|---|---|
| author | A. G. Kedrova S. E. Krasilnikov A. I. Berishvili E. A. Zvezdkina |
| author_facet | A. G. Kedrova S. E. Krasilnikov A. I. Berishvili E. A. Zvezdkina |
| author_sort | A. G. Kedrova |
| collection | DOAJ |
| description | The incidence of uterine cancer in Russia increased by 28.8 % over the last 10 years. This trend is partly associated with an increasing prevalence of overweight and aging of the female population. Despite the fact that uterine cancer is limited to the uterine body in 84 % of cases, searching for new treatment regimens for patients with progressive disease is still relevant because of their poor outcomes of chemotherapy and high mortality among patients with stage III– IV cancer.The aim of this study was to present our own view on the effectiveness of lenvatinib + pembrolizumab in patients with advanced or recurrent endometrial cancer on the basis of international and own experience.The international experience with lenvatinib + pembrolizumab for advanced endometrial cancer without high microsatellite instability or impairments of DNA repair mechanisms after disease progression following previous systemic therapy showed their efficacy (38.3 %), while the effect lasting more than 6 months was observed in 69 % of cases. We report two cases of progressive uterine cancer in patients who developed complete clinical remission and demonstrated good tolerability of the therapy. |
| format | Article |
| id | doaj-art-71d4fb0b3b8f447abcc5e12db8491491 |
| institution | DOAJ |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2022-05-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-71d4fb0b3b8f447abcc5e12db84914912025-08-20T03:01:59ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272022-05-0118110311010.17650/1994-4098-2022-18-1-103-110730Expanding therapeutic opportunities for progressive uterine cancer: clinical experienceA. G. Kedrova0S. E. Krasilnikov1A. I. Berishvili2E. A. Zvezdkina3Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation; Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Medical and Biological Agency of RussiaInstitute of Oncology and Neurosurgery, E. N. Meshalkin National Medical Research Center, Ministry of Health of RussiaFederal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation; Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Medical and Biological Agency of RussiaL.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow Healthcare Department; O. K. Skobelkin State Research Center for Laser Medicine, Federal Medical and Biological Agency of the Russian FederationThe incidence of uterine cancer in Russia increased by 28.8 % over the last 10 years. This trend is partly associated with an increasing prevalence of overweight and aging of the female population. Despite the fact that uterine cancer is limited to the uterine body in 84 % of cases, searching for new treatment regimens for patients with progressive disease is still relevant because of their poor outcomes of chemotherapy and high mortality among patients with stage III– IV cancer.The aim of this study was to present our own view on the effectiveness of lenvatinib + pembrolizumab in patients with advanced or recurrent endometrial cancer on the basis of international and own experience.The international experience with lenvatinib + pembrolizumab for advanced endometrial cancer without high microsatellite instability or impairments of DNA repair mechanisms after disease progression following previous systemic therapy showed their efficacy (38.3 %), while the effect lasting more than 6 months was observed in 69 % of cases. We report two cases of progressive uterine cancer in patients who developed complete clinical remission and demonstrated good tolerability of the therapy.https://ojrs.abvpress.ru/ojrs/article/view/940uterine cancerrecurrent endometrial cancerendometrial cancer progressionlenvatinibpembrolizumabchemotherapyimmunotherap |
| spellingShingle | A. G. Kedrova S. E. Krasilnikov A. I. Berishvili E. A. Zvezdkina Expanding therapeutic opportunities for progressive uterine cancer: clinical experience Опухоли женской репродуктивной системы uterine cancer recurrent endometrial cancer endometrial cancer progression lenvatinib pembrolizumab chemotherapy immunotherap |
| title | Expanding therapeutic opportunities for progressive uterine cancer: clinical experience |
| title_full | Expanding therapeutic opportunities for progressive uterine cancer: clinical experience |
| title_fullStr | Expanding therapeutic opportunities for progressive uterine cancer: clinical experience |
| title_full_unstemmed | Expanding therapeutic opportunities for progressive uterine cancer: clinical experience |
| title_short | Expanding therapeutic opportunities for progressive uterine cancer: clinical experience |
| title_sort | expanding therapeutic opportunities for progressive uterine cancer clinical experience |
| topic | uterine cancer recurrent endometrial cancer endometrial cancer progression lenvatinib pembrolizumab chemotherapy immunotherap |
| url | https://ojrs.abvpress.ru/ojrs/article/view/940 |
| work_keys_str_mv | AT agkedrova expandingtherapeuticopportunitiesforprogressiveuterinecancerclinicalexperience AT sekrasilnikov expandingtherapeuticopportunitiesforprogressiveuterinecancerclinicalexperience AT aiberishvili expandingtherapeuticopportunitiesforprogressiveuterinecancerclinicalexperience AT eazvezdkina expandingtherapeuticopportunitiesforprogressiveuterinecancerclinicalexperience |